Senior Oncology Account Manager

Genmab appoints Séverine Lemoine as General Manager for France. Local Media Release - France Genmab A/S (Nasdaq: GMAB) today announced the appointment of Séverine Lemoine as General Manager for France. The announcement advances the company's work to expand its presence in Europe and bring its innovative antibody-based medicines to more patients with cancer. Founded in 1999 in Copenhagen, Genmab is an international biotech company that specializes in antibody-based science. As part of the company's growth into commercial markets in Europe, Genmab is now building its presence in France. As General Manager, Séverine will lead Genmab's operations in France, including building the company's local footprint, driving the success of future product launches, and contributing positively to the local life sciences ecosystem. "We are delighted to welcome Séverine to Genmab at this pivotal stage of our growth in Europe," said Brad Bailey, Executive Vice President and Chief Commercial Officer of Genmab. "Séverine's experience building high-performing teams and successfully launching oncology products, combined with her extensive knowledge of the French healthcare landscape, make her a highly qualified leader to help guide Genmab's introduction to this important market." Séverine brings more than 20 years of leadership experience in oncology across biotech and pharma, having held senior leadership positions at Moderna, Seagen, Roche, Novartis, and AstraZeneca. Séverine joins Genmab with a strong track record of building business operations for biopharma companies in France, developing high-performing teams, and successfully launching new oncology medicines, with focus in women's cancers. "I am honored to join Genmab, a leader in antibody innovation with a compelling purpose to transform patients' lives," said Séverine Lemoine. "France has long been a center of excellence in oncology research and patient care, and together with our talented team and partners, I look forward to building Genmab's presence in France and delivering meaningful impact for patients and the healthcare community." Séverine holds a Doctor of Pharmacy degree (Université René Descartes - Paris V, 2000) and earned a Master's in Marketing Management in 2001 from the ESSEC Healthcare Chair (ESSEC Business School). About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO(R) antibody medicines. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow Genmab on LinkedIn and X. This Media Release contains forward-looking statements. The words "believe," "expect," "anticipate," "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause its actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of its products, its inability to manage growth, the competitive environment in relation to its business area and markets, its inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of its patents and proprietary rights, its relationships with affiliated entities, changes and developments in technology which may render its products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab(R); the Y-shaped Genmab logo(R); Genmab in combination with the Y-shaped Genmab logo(R); HuMax(R); DuoBody(R); HexaBody(R); DuoHexaBody(R), HexElect(R) and KYSO(R)

| Source: Media Release COPENHAGEN, Denmark; November 18, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have priced their previously announced offering of $1.5 billion of 6.250% senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of 7.250% senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”). The issue price of the Notes is 100.000%. The offering is expected to close on December 3, 2025, subject to the satisfaction of customary closing conditions. Genmab also announced that it has completed the previously announced syndication of the new $2.0 billion senior secured term loan “B” facility, which term loan “B” facility is in addition to the $1.0 billion senior secured term loan “A” facility and $500 million senior secured revolving credit facility (collectively, the “New Credit Facilities”) that Genmab previously syndicated to certain lenders as part of the financing for the pending acquisition (the “Acquisition”) of Merus N.V. (“Merus”). Genmab intends to use the net proceeds from this offering of the Notes, together with borrowings under the New Credit Facilities and cash on hand, to fund the consideration payable in connection with the Acquisition of Merus and related fees and expenses in connection with the Acquisition, the borrowings under the New Credit Facilities and the issuance of the Notes. Prior to the Acquisition closing, the Notes and the related guarantees from Genmab subsidiaries will be secured solely by segregated accounts of Genmab in which the gross proceeds of the Notes will be held. Following the purchase of all Merus common shares tendered in the previously announced tender offer by Genmab, the Secured Notes will be secured by a first priority security interest in certain assets of Genmab and its subsidiaries that will guarantee the obligations under the New Credit Facilities, in accordance with certain customary practices in the relevant jurisdictions, and subject to certain thresholds, exceptions and permitted liens. The Secured Notes will be unconditionally guaranteed on a senior secured basis and the Unsecured Notes will be unconditionally guaranteed on a senior unsecured basis by certain subsidiaries of Genmab that will guarantee the obligations under the New Credit Facilities. The indentures governing the Notes are expected to contain customary covenants that, among other things, restrict, with certain exceptions, the ability of each of Genmab and its subsidiaries to incur additional debt, pay dividends, make certain other restricted payments, incur debt secured by liens, dispose of assets, engage in consolidations and mergers or sell or transfer all or substantially all of its assets. The Notes have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other securities laws and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from the registration requirements of or in a transaction not subject to the Securities Act and any state or other applicable securities laws. Accordingly, the offering of the Notes is available only to persons who are either (1) reasonably believed to be “qualified institutional buyers” as defined in Rule 144A under the Securities Act or (2) non-U.S. persons outside the United States pursuant to Regulation S under the Securities Act. The Notes will be subject to restrictions on transferability and resale and may not be transferred or resold except in compliance with the registration requirements of the Securities Act or pursuant to an exemption therefrom and in compliance with any state or other applicable securities laws. This announcement shall not constitute an offer to sell or a solicitation of an offer to purchase any securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. The offering of the Notes may be made only by means of an offering memorandum. Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T: +1 609 524 0065; E: [email protected] Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: [email protected] Forward-looking Statements In this announcement, we make statements concerning our expectations, beliefs, plans, objectives, goals, strategies, and future events or performance, including, but not limited to, the statements about the offering of Notes, our intention to issue the Notes at the closing, and the expected use of proceeds. Genmab cautions investors that any forward-looking statements or projections made by Genmab, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in Genmab's filings with the SEC, including those included in Genmab's most recent Annual Report on Form 20-F, which is available at www.genmab.com and www.sec.gov Genmab is providing the information in this announcement as of this date, and Genmab does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo ® ; HuMax ® ; DuoBody ® ; HexaBody ® ; DuoHexaBody ® , HexElect ® and KYSO ® Media Release no. 24 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 Genmab A/S Carl Jacobsens Vej 30 2500 Valby Denmark Attachment Attachments 181125_i24_Pricing...

Genmab to showcase latest blood cancer treatment advancements at 2025 American Society of Hematology (ASH) Annual Meeting. Nov 3, 2025 at 3:05 PM CET Media Release COPENHAGEN, Denmark; November 3, 2025 * More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader range of B-cell malignancies * New data demonstrate potential of epcoritamab in first and second-line settings in follicular lymphoma (FL) and first-line in diffuse large B-cell lymphoma (DLBCL) * Results from Phase 3 EPCORE FL-1 trial, evaluating epcoritamab in combination with rituximab and lenalidomide (R[2]) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) accepted for oral presentation Genmab A/S (Nasdaq: GMAB) today announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell non-Hodgkin's lymphoma (NHL) subtypes, will be presented at the 67th Annual Meeting and Exposition of the American Society of Hematology (ASH), in Orlando, Florida, and online, December 6-9. Data from the epcoritamab development program will showcase its expanding clinical profile and potential utility in earlier lines of therapy with a fixed treatment duration. Presentations include three oral sessions supporting the potential of epcoritamab in the first- and second-line setting in patients with follicular lymphoma (FL) and two oral presentations evaluating epcoritamab in the first-line setting in patients with diffuse large B-cell lymphoma (DLBCL). Additionally, two oral presentations will summarize the efficacy and safety of epcoritamab as monotherapy and in combination for patients with Richter transformation (RT). "The breadth and depth of data evaluating epcoritamab at this year's American Society of Hematology meeting spotlight the growing body of clinical evidence supporting the potential of epcoritamab and underscore our commitment to developing epcoritamab as a potential core therapy across a range of B-cell malignancies," said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. "We look forward to sharing our data at ASH, including the full pivotal results from the Phase 3 EPCORE FL-1 trial evaluating epcoritamab in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma." 2025 R&D Update and ASH Data Review On Thursday, December 11 at 11:00 a.m. ET/5:00 p.m. CEST, Genmab will host its 2025 R&D Update and ASH Data Review. The event will be virtual and webcast live. Details, including the webcast link and registration will be available on www.genmab.com. This meeting is not an official program of the ASH Annual Meeting. All abstracts accepted for presentation have been published and may be accessed on the ASH website. The following abstracts evaluating epcoritamab have been accepted for presentation at ASH: